Skip to content
AnalystLens

ABBOTT LABORATORIESABT

Sector
Healthcare
Industry
Pharmaceutical Preparations
Exchange
NYSE

Stock Price $ABT

Latest filings

You are here#9 of 40 in Healthcare by market cap

Filing record · 2016–202610-K1110-Q328-K131

ABT filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 131 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Feb ’17Feb ’17
  2. FY2018 annual report10-K · Feb ’19Feb ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Dec ’25Dec ’25

01—Key figures

Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  19. $44.33B
YoY changeLargest recent move+31.3%in FY17Latest +5.7%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →
All ABT Financial Metrics59 metrics

Income Statement16

Balance Sheet23

Cash Flow15

Per Share5

02—Overview

ABBOTT LABORATORIES Financial Overview 2021–2025

Updated Jul 10, 2026

Abbott Laboratories' $20.6 billiona acquisition of Exact Sciences in Q1 2026 signals a definitive end to its pandemic-era identity. By issuing $20 billion in debt to capture the cancer diagnostics market, the company proved it is aggressively pivoting toward its next wave of structural expansion. The core investment thesis is clear: despite a multi-year secular drag from vanishing COVID-19 test revenue, Abbott’s underlying Medical Devices portfolio—anchored by continuous glucose monitors—has consistently driven the business back to sustainable, organic growth.

Navigating the post-pandemic hangover required a massive internal rotation, reflected in how earnings per share contracted from the testing-fueled peak of $3.94b in FY2021 to a more normalized $3.72 in FY2025. Over that span, the company absorbed severe headwinds, including a 63.3% drop in Rapid Diagnostics sales in FY2023 and a volatile U.S. infant formula recall. Yet, Abbott successfully replaced those lost revenues with core medical technology sales, pushing total net sales to $44.3 billion in FY2025. The Medical Devices segment experienced 12.6% growth that year, supercharged by its FreeStyle Libre diabetes franchise, which generated $6.4 billion in sales during FY2024. The market has largely rewarded this successful transition away from pandemic windfalls; at the close of FY2025, Abbott traded at 33.7x earnings with a share price of $125.29.

Recent Developments (Q4 2025 and Q1 2026)

Following a solid close to Q4 2025, Abbott’s Q1 2026 performance revealed the immediate margin pressure of its recent strategic shift. Total net sales jumped 7.8% year-over-year to $11.164 billionc, bolstered by a 13.2% surge in Established Pharmaceuticals. However, net earnings dropped to $1.077 billion. This reduced diluted EPS to $0.61 from $0.76 in the prior year due to higher operating and interest costs from integrating its new cancer diagnostics division. Total long-term debt now stands at $29.638 billion.

In April, the company secured preliminary court approval to settle its infant formula shareholder derivative litigation. Bulls will argue that robust top-line momentum and a 6.8% dividend hike to $0.63d per share demonstrate resilient cash generation. Conversely, bears warn that sliding Nutritional Products sales, which fell 6.0%, alongside elevated debt servicing will compress near-term profitability. After a recent price pullback, the stock appears cheaply valued, trading at 24.6x earnings at $91.33 as of the April 29, 2026 reporting date.

What to watch: margin stabilization as integration costs normalize; finalization of the infant formula litigation settlement.

03—Filings

Recent SEC Filings

  1. 8-KABBOTT LABORATORIES 8-K Report, Corporate Update (Oct 21, 2026)Abbott Laboratories (ABT) announced its intention to separate its global Nutrition business into an independent, publicly traded company. This strategic move aims to unlock distinct growth and value-creation opportunities for both the standalone Nutrition entity and the remaining Abbott healthcare business. The new Nutrition company is projected to have approximately $8.5 billion in annual sales and will focus on the rapidly growing healthy nutrition market with iconic brands like Similac, PediaSure, and Ensure. Following the separation, Abbott will continue as a diversified healthcare leader with approximately $42 billion in sales, concentrating on its higher-growth, innovation-driven portfolio in medical devices, diagnostics, and established medicines. The separation is anticipated to be completed by the end of 2027 and is structured as a tax-free distribution of shares to Abbott shareholders, who will then own stakes in both entities. This move is expected to allow for more aligned capital allocation and distinct strategic focus for each business.
  2. 8-KABBOTT LABORATORIES 8-K Report, Financial Results (Oct 21, 2026)Abbott Laboratories (ABT) reported strong third-quarter 2026 results, with total reported sales increasing by 14.5% and comparable sales growing by 7.0%. The company reaffirms its full-year 2026 adjusted diluted earnings per share (EPS) guidance of $5.50 to $5.55, tightening the range. This performance was driven by broad-based growth across its key business segments, including Diagnostics and Medical Devices, with notable contributions from new product approvals and market expansions. The report also details significant progress in product innovation and regulatory approvals, including the FDA approval of Libre® Duo, a dual glucose-ketone sensor, and the CE Mark for the Amulet 360™ Left Atrial Appendage Occluder. These advancements, coupled with reaffirmed financial guidance, suggest continued positive momentum for Abbott Laboratories heading into the final quarter of the year.
  3. 8-KABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Aug 20, 2026)On August 20, 2026, Abbott Laboratories (ABT) disclosed agreements to resolve a portion of its litigation over its specialty preterm infant formulas. Under the agreements, Abbott will resolve the Gill case, a July 2024 Missouri jury verdict of $495 million that the Missouri Court of Appeals affirmed in May 2026, along with necrotizing enterocolitis (NEC) claims on behalf of roughly 2,000 additional infants, for an aggregate of approximately $670 million. Rather than continue appealing or pay the roughly $600 million Gill judgment plus accrued interest, Abbott chose to settle. The company stresses that the agreements are a compromise of disputed claims, not an admission of liability. The filing signals a potentially meaningful step toward containing a long-running overhang on the company's nutritionals business. Abbott cites recent favorable rulings, including a Seventh Circuit affirmance of a pretrial judgment in the first federal MDL bellwether case, a June 2026 Illinois appellate reversal of a $60 million verdict against Mead Johnson, and a March 2026 Florida dismissal based on the learned intermediary doctrine. Following the settlements, about 1,700 lawsuits involving roughly 12,700 infants remain pending. Abbott says that population includes claims it considers improper, such as claims naming both Abbott and Mead Johnson without identifying the formula used, claims involving infants diagnosed with NEC before receiving any formula, claims involving infants never diagnosed with NEC, and duplicate filings across jurisdictions, and that it continues working to eliminate them. For investors, the key takeaways are the size of the cash outlay relative to the company's scale, the absence of any admission of liability, and the remaining claim count, which means the litigation is not yet resolved. The filing does not disclose the accounting impact, timing of payments, or whether the settlement amount was already reserved, so investors should look to subsequent SEC reports for those details.
  4. 8-KABBOTT LABORATORIES 8-K Report, Financial Results (Jul 16, 2026)Abbott reported second-quarter 2026 net sales of $12.593 billion, up 13.0% on a reported basis and 4.8% on a comparable basis. The reported growth was driven mainly by the March 23, 2026 acquisition of Exact Sciences, which added $811 million to Q2 sales and is consolidated as Abbott's Cancer Diagnostics business. Comparable growth was led by Medical Devices (+8.4%, with Electrophysiology and Diabetes Care strong) and Established Pharmaceuticals (+8.7%), while Nutrition declined 3.6% and Rapid/Molecular Diagnostics fell 8.0% on lower respiratory virus testing. GAAP results were weaker. GAAP diluted EPS was $0.53 versus $1.01 a year earlier, and GAAP net earnings fell 47.8% to $928 million. The decline reflects $1.362 billion of after-tax specified items ($0.78 per share), including $385 million of legal reserves tied to an agreed-in-principle settlement, intangible amortization of $658 million (up from $420 million), and acquisition-related costs. Interest expense rose to $299 million from $50 million, and the effective GAAP tax rate was 39.1%, inflated by roughly $240 million of adjustments related to a previously recognized non-cash deferred tax benefit and about $110 million of net tax expense on prior-year tax positions. Adjusted diluted EPS rose 4.0% to $1.31 from $1.26. Management reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% and raised the adjusted diluted EPS range to $5.45 to $5.60 from $5.38 to $5.58, implying a modest midpoint increase. Third-quarter adjusted EPS is guided to $1.38 to $1.46. Management expects sales and earnings growth to accelerate in the second half. Abbott also returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 per share.
  5. 8-KABBOTT LABORATORIES 8-K Report, Executive Changes (Apr 27, 2026)Abbott Laboratories (ABT) announced significant corporate governance updates following its Annual Shareholder Meeting on April 24, 2026. A key development is the approval of the Abbott Laboratories 2026 Incentive Stock Program, which will replace the previous 2017 program. This new program allows for a broad range of equity-based awards to employees and non-employee directors, with a maximum of 140,000,000 shares available, plus additional shares from the prior program's unused reserves. The program's adoption was overwhelmingly approved by shareholders, indicating strong support for the company's long-term incentive strategy. Additionally, the Board of Directors has been expanded from twelve to thirteen members, effective April 24, 2026. Shareholders also re-elected the entire slate of directors and ratified the appointment of Ernst & Young LLP as the company's auditors. The compensation of named executive officers was approved in an advisory vote, reflecting shareholder confidence in management's remuneration practices. These changes underscore Abbott's commitment to robust governance and aligning executive incentives with shareholder interests.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.